The network pharmacology and pathway enrichment analysis predicted that EGFR, PI3K, and AKT1 was increasingly associated pathway with the anti-tumor properties of 18α-GA in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.